Controls serum phosphorus. ANDA 207179, held by Aurobindo Pharma. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 207179 (Sevelamer Carbonate), held by Aurobindo Pharma, was first approved by FDA on Jul 17, 2017, with 3 approved supplements and 0 published complete response letters.
Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. Pediatric use information is approved for Genzyme Corporation’s Renvela (sevelamer carbonate) tablets and Renvela (sevelamer carbonate) for oral suspension. However, due to Genzyme Corporation’s marketing exclusivity rights, these drug products are not labeled with that pediatric information.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Rx |
| Apr 30, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 17, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters